Organization · Venture Capital
Karolinska Development
Karolinska Development AB is a publicly-listed investment company based in Solna, Sweden, focusing on early-stage life sciences companies. It leverages access to medical innovations from leading Nordic universities to build and grow its portfolio.
Overview
What Karolinska Development does
What Karolinska Development is
Karolinska Development AB is a publicly-listed investment company based in Solna, Sweden, focusing on early-stage life sciences companies. It leverages access to medical innovations from leading Nordic universities to build and grow its portfolio.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2003
- Approximate age
- About 23 years
- Structured capabilities
- Funder
- Last reviewed
- April 23, 2026
Official channels
Find Karolinska Development elsewhere
Open the official website or a supported primary organization account.
Capability profile
Karolinska Development as a funder
Investment thesis
Karolinska Development invests in Nordic life science companies focused on serious diseases, leveraging innovations from leading research institutions.
Focus narrative
Karolinska Development focuses on early-stage investments in pharmaceutical and medtech companies, particularly those progressing through phase 2 clinical trials or early commercialization phases. The organization employs a syndication model, partnering with other leading investors in the life sciences sector to maximize value generation and patient benefit.
Value beyond capital
Karolinska Development adds value to its portfolio companies through its extensive network and expertise in life sciences. The organization provides strategic guidance, access to funding, and partnerships with other institutional investors, enhancing the growth potential of its portfolio companies. Its focus on patient benefit ensures that investments align with meaningful health outcomes.
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Series B
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 11
- Recorded notable exits
- Forendo Pharma and Xspray
Portfolio context
Karolinska Development's portfolio includes notable companies such as: Forendo Pharma: Developing a new treatment for endometriosis, acquired by Organon in 2021 for USD 945 million. BioArctic: Targets Alzheimer’s and Parkinson’s diseases, listed on NASDAQ Stockholm in 2017. Xspray: Developed improved versions of marketed pharmaceuticals, with a successful exit in 2015. OssDsign: Focuses on orthobiologics, listed on Nasdaq First North Growth Market in 2019. Modus Therapeutics: Developing treatments for chronic kidney disease, also listed on Nasdaq First North Growth Market.
Common questions
What to know about Karolinska Development
Upseed classifies Karolinska Development under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 23, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.